Vascarta’s groundbreaking research collaboration with Dr. Abdu Alayash of the FDA, formalized on December 1, 2022, marks a pivotal step in advancing therapeutic innovation. This partnership focuses on exploring the potential of Vascarta’s patented topical and transdermal curcumin technology for addressing critical conditions like sepsis and other inflammatory diseases. By combining Vascarta’s expertise in botanical pharmaceuticals with Dr. Alayash’s extensive knowledge of redox biology and hemoglobin-based therapeutics, the collaboration aims to develop cutting-edge solutions that could significantly enhance patient outcomes. This alliance underscores Vascarta’s commitment to driving impactful research and delivering transformative health solutions.